WT5
MCID: WLM018
MIFTS: 63

Wilms Tumor 5 (WT5)

Categories: Blood diseases, Cancer diseases, Fetal diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Wilms Tumor 5

MalaCards integrated aliases for Wilms Tumor 5:

Name: Wilms Tumor 5 57
Wilms Tumor 25 55 6 43 40
Wilms Tumor Susceptibility-5 57 29 13
Nephroblastoma 25 72
Wt5 57 74
Hereditary Susceptibility to Wilms Tumor 5 74
Wilms Tumor and Radial Bilateral Aplasia 72
Kidney, Adenomyosarcoma, Embryonal 25
Kidney, Carcinosarcoma, Embryonal 25
Wilms Tumor, Susceptibility to 57
Kidney, Embryonal Mixed Tumor 25
Embryonal Adenosarcoma 25
Renal Cancer, Wilms 25
Wilms Tumor, Type 5 40
Wilms Tumor ; Wtsl 57
Embryonal Nephroma 25
Kidney Wilms Tumor 25
Renal Adenosarcoma 25
Renal Wilms Tumor 25
Kidney, Embryoma 25
Wilms' Tumor 25
Tumor, Wilms 25
Nephroma 25
Wtsl 57

Characteristics:

OMIM:

57
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
most cases are sporadic
tumor suppressor gene


HPO:

32

Classifications:



External Ids:

MedGen 42 C1832099
UMLS 72 C0027708 C1832099

Summaries for Wilms Tumor 5

Genetics Home Reference : 25 Wilms tumor is a form of kidney cancer that primarily develops in children. Nearly all cases of Wilms tumor are diagnosed before the age of 10, with two-thirds being found before age 5. Wilms tumor is often first noticed because of abdominal swelling or a mass in the kidney that can be felt upon physical examination. Some affected children have abdominal pain, fever, a low number of red blood cells (anemia), blood in the urine (hematuria), or high blood pressure (hypertension). Additional signs of Wilms tumor can include loss of appetite, weight loss, nausea, vomiting, and tiredness (lethargy). Wilms tumor can develop in one or both kidneys. About 5 to 10 percent of affected individuals develop multiple tumors in one or both kidneys. Wilms tumor may spread from the kidneys to other parts of the body (metastasize). In rare cases, Wilms tumor does not involve the kidneys and occurs instead in the genital tract, bladder, abdomen, chest, or lower back. It is unclear how Wilms tumor develops in these tissues. With proper treatment, children with Wilms tumor have a 90 percent survival rate. However, the risk that the cancer will come back (recur) is between 15 and 50 percent, depending on traits of the original tumor. Tumors usually recur in the first 2 years following treatment and develop in the kidneys or other tissues, such as the lungs. Individuals who have had Wilms tumor may experience related health problems or late effects of their treatment in adulthood, such as decreased kidney function, heart disease, and development of additional cancers.

MalaCards based summary : Wilms Tumor 5, also known as wilms tumor, is related to aniridia 1 and wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome, and has symptoms including abdominal pain An important gene associated with Wilms Tumor 5 is POU6F2 (POU Class 6 Homeobox 2), and among its related pathways/superpathways are Adhesion and Proteoglycans in cancer. The drugs Miconazole and Itraconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, myeloid and t cells, and related phenotypes are nephroblastoma and cardiovascular system

MedlinePlus : 43 Wilms tumor is a rare type of kidney cancer. It causes a tumor on one or both kidneys. It usually affects children, but can happen in adults. Having certain genetic conditions or birth defects can increase the risk of getting it. Children that are at risk should be screened for Wilms tumor every three months until they turn eight. Symptoms include a lump in the abdomen, blood in the urine, and a fever for no reason. Tests that examine the kidney and blood are used to find the tumor. Doctors usually diagnose and remove the tumor in surgery. Other treatments include chemotherapy and radiation and biologic therapies. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 74 Hereditary susceptibility to Wilms tumor 5: Pediatric malignancy of kidney and one of the most common solid cancers in childhood.

More information from OMIM: 601583 PS194070

Related Diseases for Wilms Tumor 5

Diseases in the Hereditary Wilms' Tumor family:

Wilms Tumor 1 Wilms Tumor 2
Wilms Tumor 3 Wilms Tumor 4
Wilms Tumor 5 Wilms Tumor 6
Familial Wilms Tumor 2

Diseases related to Wilms Tumor 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 812)
# Related Disease Score Top Affiliating Genes
1 aniridia 1 32.7 WT1 PAX6 IGF2
2 wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome 32.7 WT1 PAX6 IGF2
3 hereditary wilms' tumor 31.9 WT1 PAX6 IGF2 CDKN1C
4 hemihyperplasia, isolated 30.6 WT1 IGF2 H19 CDKN1C
5 silver-russell syndrome 30.5 IGF2 H19 CDKN1C
6 nephrogenic adenofibroma 30.5 WT1 PAX8 PAX2
7 renal cell carcinoma, nonpapillary 30.3 WT1 PAX8 PAX2 H19
8 umbilical hernia 30.2 IGF2 H19 CDKN1C
9 adrenocortical carcinoma, hereditary 30.1 IGF2 H19 CTNNB1 CDKN1C
10 ovarian brenner tumor 30.0 WT1 PAX8 PAX2
11 female reproductive endometrioid cancer 30.0 WT1 CTNNB1
12 hepatoblastoma 29.6 IGF2 H19 GPC3 CTNNB1 CDKN1C
13 focal segmental glomerulosclerosis 29.4 WT1 SYNPO PAX2 CTNNB1 CDKN1C
14 rhabdomyosarcoma 29.2 SLC22A18 IGF2 H19 CCN3 CCN1
15 beckwith-wiedemann syndrome 28.0 WT1 SLC22A18 NAP1L4 IGF2 H19 GPC3
16 wilms tumor 1 26.6 WTAP WT1 SYNPO SLC22A18 PRDM2 POU6F2
17 cervical wilms' tumor 12.7
18 global developmental delay, lung cysts, overgrowth, and wilms tumor 12.6
19 wilms tumor 4 12.5
20 epithelial predominant wilms' tumor 12.5
21 stromal predominant kidney wilms' tumor 12.5
22 renal wilms' tumor 12.5
23 wilms tumor 3 12.5
24 blastema predominant kidney wilms' tumor 12.5
25 familial wilms tumor 2 12.4
26 cellular congenital mesoblastic nephroma 12.4
27 wilms tumor predisposition 12.4
28 adult mesoblastic nephroma 12.4
29 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.4
30 mixed cell type kidney wilms' tumor 12.3
31 metachronous kidney wilms' tumor 12.3
32 classic congenital mesoblastic nephroma 12.2
33 frasier syndrome 11.8
34 mulibrey nanism 11.7
35 hyperparathyroidism 2 with jaw tumors 11.7
36 simpson-golabi-behmel syndrome 11.7
37 mosaic variegated aneuploidy syndrome 3 11.7
38 mosaic variegated aneuploidy syndrome 11.7
39 li-fraumeni syndrome 11.6
40 li-fraumeni syndrome 2 11.6
41 2q37 deletion syndrome 11.6
42 bohring-opitz syndrome 11.6
43 thauvin-robinet-faivre syndrome 11.6
44 dicer1-related disorders 11.5
45 dicer1-related pleuropulmonary blastoma cancer predisposition syndrome 11.5
46 denys-drash syndrome 11.5
47 metanephric adenoma 11.5
48 embryoma 11.5
49 wilms tumor and radial bilateral aplasia 11.4
50 mixed epithelial stromal tumour 11.3

Graphical network of the top 20 diseases related to Wilms Tumor 5:



Diseases related to Wilms Tumor 5

Symptoms & Phenotypes for Wilms Tumor 5

Human phenotypes related to Wilms Tumor 5:

32
# Description HPO Frequency HPO Source Accession
1 nephroblastoma 32 HP:0002667

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Kidneys:
nephroblastoma (wilms tumor)

Neoplasia:
nephroblastoma (wilms tumor)

Clinical features from OMIM:

601583

UMLS symptoms related to Wilms Tumor 5:


abdominal pain

MGI Mouse Phenotypes related to Wilms Tumor 5:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 CCN1 CCN3 CTNNB1 GPC3 IGF2 PAX2
2 embryo MP:0005380 9.96 CCN1 CTNNB1 FZD6 GPC3 IGF2 PAX2
3 mortality/aging MP:0010768 9.73 CCN1 CCN3 CTNNB1 FZD6 GPC3 IGF2
4 limbs/digits/tail MP:0005371 9.63 CCN3 CTNNB1 FZD6 GPC3 IGF2 PAX8
5 renal/urinary system MP:0005367 9.28 CCN3 CTNNB1 GPC3 IGF2 PAX2 PAX6

Drugs & Therapeutics for Wilms Tumor 5

Drugs for Wilms Tumor 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 256)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
3
Oxytetracycline Approved, Investigational, Vet_approved Phase 4 79-57-2 5280972 54715139
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
6
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
7
Dactinomycin Approved, Investigational Phase 4 50-76-0 457193 2019
8
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
9
Pirarubicin Investigational Phase 4 72496-41-4
10 Hormone Antagonists Phase 4
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
12 Antifungal Agents Phase 4
13 14-alpha Demethylase Inhibitors Phase 4
14 Cytochrome P-450 CYP3A Inhibitors Phase 4
15 Cytochrome P-450 Enzyme Inhibitors Phase 4
16 Steroid Synthesis Inhibitors Phase 4
17
Hydroxyitraconazole Phase 4
18
Liposomal doxorubicin Phase 4 31703
19 Antibiotics, Antitubercular Phase 4
20 Nucleic Acid Synthesis Inhibitors Phase 4
21 Tubulin Modulators Phase 4
22 Antimitotic Agents Phase 4
23
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
24
Etoposide Approved Phase 3 33419-42-0 36462
25
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
26
Sulfamethoxazole Approved Phase 3 723-46-6 5329
27
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
28
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
29
Ribavirin Approved Phase 3 36791-04-5 37542
30
Palivizumab Approved, Investigational Phase 3 188039-54-5
31
Captopril Approved Phase 3 62571-86-2 44093
32
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
33
Acyclovir Approved Phase 3 59277-89-3 2022
34
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
35
Daunorubicin Approved Phase 3 20830-81-3 30323
36
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
37
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
38
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
39
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
40
Histamine Approved, Investigational Phase 3 51-45-6 774
41
Cyproheptadine Approved Phase 3 129-03-3 2913
42
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
43
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
44 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
45 Alkylating Agents Phase 3
46 Antineoplastic Agents, Phytogenic Phase 3
47 Immunologic Factors Phase 3
48 Topoisomerase Inhibitors Phase 3
49 Immunosuppressive Agents Phase 3
50 Antirheumatic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 203)
# Name Status NCT ID Phase Drugs
1 A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer Unknown status NCT00491946 Phase 4 Actinomycin-D;Vincristine
2 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
3 A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma. Not yet recruiting NCT03892330 Phase 4 Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
4 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
5 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
6 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
7 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
8 Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
9 NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
10 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
11 Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR Completed NCT00179829 Phase 2, Phase 3
12 National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
13 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
14 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
15 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
16 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
17 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
18 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
19 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
20 A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD Completed NCT01371981 Phase 3 Asparaginase;Bortezomib;Cytarabine;Daunorubicin Hydrochloride;Etoposide;Mitoxantrone Hydrochloride;Sorafenib Tosylate
21 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
22 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
23 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor Active, not recruiting NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate
25 Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) Not yet recruiting NCT03669783 Phase 3 treatment Vincristin;treatment Actinomycin-D;treatment Doxorubicin;treatment Carboplatin;Etoposide
26 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial Unknown status NCT00965224 Phase 2
28 Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study Unknown status NCT01291420 Phase 1, Phase 2
29 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
30 A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy Unknown status NCT02624388 Phase 2 Genistein;Placebo
31 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
32 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
33 Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
34 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
35 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
36 A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation Completed NCT00405327 Phase 2
37 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
38 Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
39 A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer Completed NCT00365768 Phase 2 Glutamine
40 Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia Completed NCT01095926 Phase 2 doxorubicin
41 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
42 Treatment of High Risk Renal Tumors: A Groupwide Phase II Study Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
43 Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers Completed NCT00002515 Phase 2 carboplatin;thiotepa;topotecan hydrochloride
44 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
45 Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
46 Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation Completed NCT00309907 Phase 2 methylprednisolone
47 Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies Completed NCT00038207 Phase 2 Liposomal Vincristine
48 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
49 A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias Completed NCT01154816 Phase 2 Alisertib
50 Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer Completed NCT01222780 Phase 1, Phase 2 Marqibo

Search NIH Clinical Center for Wilms Tumor 5

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Dactinomycin
Doxorubicin
Etoposide
Vincristine

Genetic Tests for Wilms Tumor 5

Genetic tests related to Wilms Tumor 5:

# Genetic test Affiliating Genes
1 Wilms Tumor Susceptibility-5 29

Anatomical Context for Wilms Tumor 5

MalaCards organs/tissues related to Wilms Tumor 5:

41
Kidney, Myeloid, T Cells, Bone, Lung, Bone Marrow, Breast

Publications for Wilms Tumor 5

Articles related to Wilms Tumor 5:

(show top 50) (show all 7048)
# Title Authors PMID Year
1
Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. 38 8 71
15459955 2004
2
Refinement within single yeast artificial chromosome clones of a minimal region commonly deleted on the short arm of chromosome 7 in Wilms tumours. 8 71
11284034 2001
3
Localization of a novel t(1;7) translocation associated with Wilms' tumor predisposition and skeletal abnormalities. 38 8
8946193 1996
4
Germline and somatic abnormalities of chromosome 7 in Wilms' tumor. 38 8
7954327 1994
5
Update on Wilms tumor. 38 17
30270120 2019
6
Pharmacotherapeutic Management of Wilms Tumor: An Update. 38 17
30604241 2019
7
Wilms tumor, pleuropulmonary blastoma, and DICER1: case report and literature review. 38 17
30097050 2018
8
The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour. 8
12618763 2003
9
Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour. 8
9690521 1998
10
Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors. 8
8938443 1996
11
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. 9 38
20166202 2010
12
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. 9 38
20435628 2010
13
Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. 9 38
20423567 2010
14
Wilms tumor suppressor 1 (WT1) and early growth response 1 (EGR1) are regulators of STIM1 expression. 9 38
20123987 2010
15
Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. 9 38
20332316 2010
16
The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells. 9 38
20204298 2010
17
Conditionally immortalized human podocyte cell lines established from urine. 9 38
19955187 2010
18
Integrative genomic analyses on interferon-lambdas and their roles in cancer prediction. 9 38
20043142 2010
19
Nuclear accumulation of beta-catenin protein indicates activation of wnt signaling in chemically induced rat nephroblastomas. 9 38
19348510 2010
20
High frequency of loss of allelic integrity at Wilms' tumor suppressor gene-1 locus in advanced breast tumors associated with aggressiveness of the tumor. 9 38
19749460 2009
21
Peptide vaccines for patients with acute myeloid leukemia. 9 38
19803762 2009
22
Myocardial adenomatoid tumor in eight cattle: evidence for mesothelial origin of bovine myocardial epithelial inclusions. 9 38
19430001 2009
23
Nuclear degradation of Wilms tumor 1-associating protein and survivin splice variant switching underlie IGF-1-mediated survival. 9 38
19605357 2009
24
WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? 9 38
19530245 2009
25
Expression of stem cell markers in the human fetal kidney. 9 38
19696931 2009
26
Calcifying nested stromal-epithelial tumors of the liver: a clinicopathologic, immunohistochemical, and molecular genetic study of 9 cases with a long-term follow-up. 9 38
19363442 2009
27
Paratesticular müllerian-type papillary serous tumor in a child. 9 38
19348511 2009
28
A novel WT1 mutation in a 46,XY boy with congenital bilateral cryptorchidism, nystagmus and Wilms tumor. 9 38
19048299 2009
29
Serous adenocarcinoma of the retroperitoneum, as a type of multifocal müllerian carcinoma. 9 38
19593619 2009
30
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. 9 38
19463768 2009
31
Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2. 9 38
19342968 2009
32
The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. 9 38
19416806 2009
33
TTF-1 expression in nephroblastoma. 9 38
19011567 2009
34
Radiosensitization by inhibiting STAT1 in renal cell carcinoma. 9 38
19100922 2009
35
WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis. 9 38
19048125 2008
36
Regulation of CRABP-II expression by MycN in Wilms tumor. 9 38
18955045 2008
37
Wilms' tumor gene 1 (WT1) in endometrial carcinoma. 9 38
18929401 2008
38
Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. 9 38
19047088 2008
39
Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. 9 38
18724243 2008
40
Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2. 9 38
18922980 2008
41
Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. 9 38
18543005 2008
42
Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. 9 38
18618575 2008
43
Brain-derived neurotrophic factor and obesity in the WAGR syndrome. 9 38
18753648 2008
44
Wilms' tumor protein (-KTS) modulates renin gene transcription. 9 38
18496514 2008
45
Ectopic Pax2 expression in chick ventral optic cup phenocopies loss of Pax2 expression. 9 38
18485342 2008
46
TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. 9 38
18535006 2008
47
The Wilms' tumor suppressor WT1 inhibits malignant progression of neoplastigenic mammary epithelial cells. 9 38
18751389 2008
48
Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. 9 38
18311776 2008
49
Expression of multidrug resistance-related protein (MRP-1), lung resistance-related protein (LRP) and topoisomerase-II (TOPO-II) in Wilms' tumor: immunohistochemical study using TMA methodology. 9 38
18795074 2008
50
In silico regulatory analysis for exploring human disease progression. 9 38
18564415 2008

Variations for Wilms Tumor 5

ClinVar genetic disease variations for Wilms Tumor 5:

6 (show top 50) (show all 100)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CTNNB1 NM_001904.4(CTNNB1): c.770C> T (p.Thr257Ile) single nucleotide variant other rs1553630452 3:41267186-41267186 3:41225695-41225695
2 TET2 NM_001127208.2(TET2): c.4456T> C (p.Ser1486Pro) single nucleotide variant other rs1553918194 4:106193994-106193994 4:105272837-105272837
3 MED12 NM_005120.3(MED12): c.131G> A (p.Gly44Asp) single nucleotide variant other rs199469672 X:70339254-70339254 X:71119404-71119404
4 POU6F2 NM_007252.4(POU6F2): c.573G> T (p.Gln191His) single nucleotide variant Pathogenic rs121918261 7:39379302-39379302 7:39339703-39339703
5 POU6F2 POU6F2, C-G, EXON 1C, 5-PRIME UTR single nucleotide variant Pathogenic
6 FZD6 NM_001164615.2(FZD6): c.346C> T (p.Arg116Ter) single nucleotide variant Pathogenic rs769116796 8:104330986-104330986 8:103318758-103318758
7 CTNNB1 NM_001904.4(CTNNB1): c.133_135del (p.Ser45del) deletion Pathogenic rs587776850 3:41266136-41266138 3:41224645-41224647
8 CTNNB1 NM_001904.4(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 3:41266137-41266137 3:41224646-41224646
9 WT1 NM_024426.6(WT1): c.381C> G (p.Pro127=) single nucleotide variant Conflicting interpretations of pathogenicity rs771681406 11:32456526-32456526 11:32434980-32434980
10 VHL NM_000551.3(VHL): c.241C> T (p.Pro81Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104893829 3:10183772-10183772 3:10142088-10142088
11 WT1 NM_024426.6(WT1): c.375C> T (p.Gly125=) single nucleotide variant Conflicting interpretations of pathogenicity rs776209354 11:32456532-32456532 11:32434986-32434986
12 MSH2 NM_000251.2(MSH2): c.2321T> C (p.Ile774Thr) single nucleotide variant Uncertain significance rs878853811 2:47705521-47705521 2:47478382-47478382
13 WT1 NM_024426.6(WT1): c.411_413GCC[5] (p.Pro141dup) short repeat Uncertain significance rs760304811 11:32456485-32456487 11:32434939-32434941
14 WT1 NM_024426.6(WT1): c.*1058G> T single nucleotide variant Uncertain significance rs886048211 11:32409546-32409546 11:32388000-32388000
15 WT1 NM_024426.6(WT1): c.*1021_*1022GT[18] short repeat Uncertain significance rs58549495 11:32409550-32409551 11:32388004-32388005
16 WT1 NM_024426.6(WT1): c.*685G> T single nucleotide variant Uncertain significance rs886048218 11:32409919-32409919 11:32388373-32388373
17 WT1 NM_024426.6(WT1): c.*614A> C single nucleotide variant Uncertain significance rs886048219 11:32409990-32409990 11:32388444-32388444
18 WT1 NM_024426.6(WT1): c.*110C> T single nucleotide variant Uncertain significance rs757474299 11:32410494-32410494 11:32388948-32388948
19 WT1 NM_024426.6(WT1): c.887+4G> A single nucleotide variant Uncertain significance rs778673400 11:32449498-32449498 11:32427952-32427952
20 WT1 NM_024426.6(WT1): c.390A> G (p.Pro130=) single nucleotide variant Uncertain significance rs886048228 11:32456517-32456517 11:32434971-32434971
21 WT1 NM_024426.6(WT1): c.162C> G (p.Ser54Arg) single nucleotide variant Uncertain significance rs776954184 11:32456745-32456745 11:32435199-32435199
22 WT1 NM_024426.6(WT1): c.-82A> C single nucleotide variant Uncertain significance rs886048236 11:32456988-32456988 11:32435442-32435442
23 WT1 NM_024426.6(WT1): c.-102C> A single nucleotide variant Uncertain significance rs886048240 11:32457008-32457008 11:32435462-32435462
24 WT1 NM_024426.6(WT1): c.-110C> T single nucleotide variant Uncertain significance rs886048241 11:32457016-32457016 11:32435470-32435470
25 WT1 NM_024426.6(WT1): c.-114T> A single nucleotide variant Uncertain significance rs886048242 11:32457020-32457020 11:32435474-32435474
26 WT1 NM_024426.6(WT1): c.-135G> A single nucleotide variant Uncertain significance rs886048243 11:32457041-32457041 11:32435495-32435495
27 WT1 NM_024426.6(WT1): c.*1021_*1022GT[14] short repeat Uncertain significance rs58549495 11:32409550-32409555 11:32388004-32388009
28 WT1 NM_024426.6(WT1): c.*1021_*1022GT[20] short repeat Uncertain significance rs58549495 11:32409550-32409555 11:32388004-32388009
29 WT1 NM_024426.6(WT1): c.*841C> A single nucleotide variant Uncertain significance rs886048213 11:32409763-32409763 11:32388217-32388217
30 SMAD4 NM_005359.5(SMAD4): c.875C> T (p.Pro292Leu) single nucleotide variant Uncertain significance rs786201404 18:48584797-48584797 18:51058427-51058427
31 WT1 NM_024426.6(WT1): c.*707C> A single nucleotide variant Uncertain significance rs886048217 11:32409897-32409897 11:32388351-32388351
32 WT1 NM_024426.6(WT1): c.*574del deletion Uncertain significance rs5030319 11:32410030-32410030 11:32388484-32388484
33 WT1 NM_024426.6(WT1): c.*460C> A single nucleotide variant Uncertain significance rs886048221 11:32410144-32410144 11:32388598-32388598
34 WT1 NM_024426.6(WT1): c.*393G> T single nucleotide variant Uncertain significance rs886048222 11:32410211-32410211 11:32388665-32388665
35 WT1 NM_024426.6(WT1): c.*159G> C single nucleotide variant Uncertain significance rs746218880 11:32410445-32410445 11:32388899-32388899
36 WT1 NM_024426.6(WT1): c.1200C> T (p.Tyr400=) single nucleotide variant Uncertain significance rs886048227 11:32417867-32417867 11:32396321-32396321
37 WT1 NM_024426.6(WT1): c.247G> T (p.Ala83Ser) single nucleotide variant Uncertain significance rs886048231 11:32456660-32456660 11:32435114-32435114
38 WT1 NM_024426.6(WT1): c.174C> G (p.Leu58=) single nucleotide variant Uncertain significance rs886048232 11:32456733-32456733 11:32435187-32435187
39 WT1 NM_024426.6(WT1): c.136G> T (p.Ala46Ser) single nucleotide variant Uncertain significance rs886048233 11:32456771-32456771 11:32435225-32435225
40 WT1 NM_024426.6(WT1): c.-76T> C single nucleotide variant Uncertain significance rs886048235 11:32456982-32456982 11:32435436-32435436
41 WT1 NM_024426.6(WT1): c.-86T> C single nucleotide variant Uncertain significance rs886048237 11:32456992-32456992 11:32435446-32435446
42 WT1 NM_024426.6(WT1): c.-94G> C single nucleotide variant Uncertain significance rs886048239 11:32457000-32457000 11:32435454-32435454
43 WT1 NM_024426.6(WT1): c.*1225T> C single nucleotide variant Uncertain significance rs886048210 11:32409379-32409379 11:32387833-32387833
44 WT1 NM_024426.6(WT1): c.*1021_*1022GT[15] short repeat Uncertain significance rs58549495 11:32409550-32409553 11:32388004-32388007
45 WT1 NM_024426.6(WT1): c.*1021_*1022GT[19] short repeat Uncertain significance rs58549495 11:32409550-32409553 11:32388004-32388007
46 WT1 NM_024426.6(WT1): c.*741G> T single nucleotide variant Uncertain significance rs886048216 11:32409863-32409863 11:32388317-32388317
47 WT1 NM_024426.6(WT1): c.*534C> T single nucleotide variant Uncertain significance rs868546165 11:32410070-32410070 11:32388524-32388524
48 WT1 NM_024426.6(WT1): c.*366C> A single nucleotide variant Uncertain significance rs886048223 11:32410238-32410238 11:32388692-32388692
49 WT1 NM_024426.6(WT1): c.*354G> T single nucleotide variant Uncertain significance rs886048224 11:32410250-32410250 11:32388704-32388704
50 WT1 NM_024426.6(WT1): c.*785C> A single nucleotide variant Uncertain significance rs886048214 11:32409819-32409819 11:32388273-32388273

UniProtKB/Swiss-Prot genetic disease variations for Wilms Tumor 5:

74
# Symbol AA change Variation ID SNP ID
1 POU6F2 p.Gln192His VAR_022419

Expression for Wilms Tumor 5

Search GEO for disease gene expression data for Wilms Tumor 5.

Pathways for Wilms Tumor 5

Pathways related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 CTNNB1 CCN3 CCN1
2 11.57 IGF2 GPC3 FZD6 CTNNB1
3 11.48 IGF2 FZD6 CTNNB1
4 10.89 WT1 SYNPO PAX2 CTNNB1 CDKN1C
5 10.36 PAX8 PAX2

GO Terms for Wilms Tumor 5

Biological processes related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 WT1 PRDM2 PAX8 PAX6 PAX2 IGF2
2 central nervous system development GO:0007417 9.86 POU6F2 PAX8 PAX6
3 animal organ morphogenesis GO:0009887 9.85 PAX6 IGF2 GPC3
4 negative regulation of epithelial cell proliferation GO:0050680 9.81 PAX6 GPC3 CDKN1C
5 inner ear morphogenesis GO:0042472 9.8 PAX8 PAX2 FZD6
6 transcription by RNA polymerase II GO:0006366 9.73 POU6F2 PAX6 PAX2
7 anatomical structure morphogenesis GO:0009653 9.68 PAX8 GPC3
8 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.67 PAX8 PAX2
9 male genitalia development GO:0030539 9.67 WT1 CTNNB1
10 urogenital system development GO:0001655 9.67 PAX8 PAX2
11 anterior/posterior axis specification GO:0009948 9.66 GPC3 CTNNB1
12 mesonephros development GO:0001823 9.66 PAX8 PAX2
13 mesenchymal to epithelial transition GO:0060231 9.65 WT1 PAX2
14 transcription, DNA-templated GO:0006351 9.65 PAX8 PAX2
15 metanephric mesenchyme development GO:0072075 9.65 WT1 PAX2
16 dorsal/ventral axis specification GO:0009950 9.64 PAX6 CTNNB1
17 cellular response to gonadotropin stimulus GO:0071371 9.64 WT1 PAX8
18 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.62 PAX8 PAX2
19 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.61 PAX8 PAX2
20 pronephros development GO:0048793 9.6 PAX8 PAX2
21 embryonic placenta morphogenesis GO:0060669 9.59 IGF2 CDKN1C
22 positive regulation of epithelial cell differentiation GO:0030858 9.58 PAX6 CTNNB1
23 metanephric S-shaped body morphogenesis GO:0072284 9.58 WT1 PAX8
24 camera-type eye development GO:0043010 9.56 WT1 PAX6 PAX2 CDKN1C
25 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.55 PAX8 PAX2
26 kidney development GO:0001822 9.55 WT1 PAX8 GPC3 CTNNB1 CDKN1C
27 metanephric nephron tubule formation GO:0072289 9.54 PAX8 PAX2
28 metanephric distal convoluted tubule development GO:0072221 9.52 PAX8 PAX2
29 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.51 PAX8 PAX2
30 cell fate determination GO:0001709 9.5 PAX6 PAX2 CTNNB1
31 pronephric field specification GO:0039003 9.49 PAX8 PAX2
32 positive regulation of metanephric DCT cell differentiation GO:2000594 9.48 PAX8 PAX2
33 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.46 PAX8 PAX2
34 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.43 PAX8 PAX2
35 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.4 PAX8 PAX2
36 metanephric epithelium development GO:0072207 9.13 WT1 PAX8 PAX2
37 branching involved in ureteric bud morphogenesis GO:0001658 9.02 WT1 PAX8 PAX2 GPC3 CTNNB1
38 regulation of transcription, DNA-templated GO:0006355 10.21 WT1 PRDM2 POU6F2 PAX8 PAX6 PAX2
39 multicellular organism development GO:0007275 10.17 WTAP POU6F2 PAX8 PAX6 PAX2 IGF2
40 positive regulation of transcription, DNA-templated GO:0045893 10.04 WT1 PAX8 PAX6 PAX2 CTNNB1 CDKN1C

Molecular functions related to Wilms Tumor 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.43 WT1 PRDM2 POU6F2 PAX8 PAX6 CTNNB1
2 integrin binding GO:0005178 9.33 IGF2 CCN3 CCN1
3 transcription regulatory region DNA binding GO:0044212 8.92 WT1 PAX8 PAX6 PAX2

Sources for Wilms Tumor 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....